VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Drop in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,441,031 shares, a drop of 27.9% from the December 31st total of 3,385,220 shares. Based on an average daily trading volume, of 1,563,145 shares, the short-interest ratio is presently 1.6 days. Approximately 6.4% of the shares of the company are short sold. Approximately 6.4% of the shares of the company are short sold. Based on an average daily trading volume, of 1,563,145 shares, the short-interest ratio is presently 1.6 days.

Trending Headlines about VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Neutral Sentiment: Lead-plaintiff deadline and class period: Multiple notices remind investors that the lead-plaintiff deadline is March 16, 2026 and define the alleged class period as April 1, 2024–December 16, 2025; this is procedural but sets the timetable for litigation consolidation and potential claims. ROSEN reminder
• Negative Sentiment: Multiple firms have filed or are soliciting class actions/investigations (Rosen, Pomerantz, Bragar Eagel & Squire, Levi & Korsinsky, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Schall, DJS, Gross Law and others). That coordinated legal activity suggests elevated litigation exposure; outcomes could include defense costs, settlements or judgment risk that would likely weigh on VTGN’s share price and financing flexibility. Representative filing/notice: Bragar notice

VistaGen Therapeutics Stock Up 3.1%

VistaGen Therapeutics stock opened at $0.56 on Friday. VistaGen Therapeutics has a 52-week low of $0.54 and a 52-week high of $5.14. The firm has a market capitalization of $22.04 million, a price-to-earnings ratio of -0.29 and a beta of 0.31. The firm has a 50-day moving average price of $1.93 and a two-hundred day moving average price of $2.95.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. Research analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Two Sigma Investments LP lifted its holdings in VistaGen Therapeutics by 223.5% in the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after purchasing an additional 199,958 shares during the period. Jane Street Group LLC acquired a new stake in VistaGen Therapeutics in the 2nd quarter valued at about $190,000. Stempoint Capital LP lifted its stake in VistaGen Therapeutics by 2.0% during the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after purchasing an additional 46,700 shares during the last quarter. AdvisorShares Investments LLC lifted its position in shares of VistaGen Therapeutics by 27.7% during the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after acquiring an additional 44,000 shares during the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of VistaGen Therapeutics during the third quarter valued at $152,000. 78.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VTGN. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a report on Wednesday, December 17th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.90 price target (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, VistaGen Therapeutics presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.